Last reviewed · How we verify

NCT05892276

Effects of CBD Oil on Memory Reconsolidation and Trauma-Related Symptoms

Withdrawn NA Last updated 9 January 2024
What this trial tests

NA trial testing Trauma Memory Reactivation in Posttraumatic Stress Disorder. Withdrawn.

Timeline
31 August 2024
Primary endpoint
31 August 2025
31 August 2025

Quick facts

Lead sponsorUniversity of Texas at Austin
PhaseNA
StatusWithdrawn
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposetreatment
Start date31 August 2024
Primary completion31 August 2025
Estimated completion31 August 2025
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Texas at Austin

Who can join

Adults 18 to 65, any sex, with Posttraumatic Stress Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to investigate the effects of cannabidiol (CBD) broad-spectrum oil on memory reconsolidation (memory storage) and trauma-related symptoms in trauma-exposed individuals after exposure to a trauma memory reactivation paradigm.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Posttraumatic Stress Disorder

Currently open trials in the same condition.

Other University of Texas at Austin trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05892276.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing